Adult Soft Tissue Sarcoma Treatments
Find Adult Soft Tissue Sarcoma Treatments
Medications for Adult Soft Tissue Sarcoma
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Adult Soft Tissue Sarcoma.
Found 13 Approved Drugs for Adult Soft Tissue Sarcoma
Doxil
Generic Name
DOXOrubicin
Doxil
Generic Name
DOXOrubicin
Form: Injection, Injectable
Method of administration: Intravenous, Intravitreal
FDA approval date: May 01, 1996
Classification: Anthracycline Topoisomerase Inhibitor
Doxil liposomal infusion is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer: After failure of platinum-based chemotherapy.
Paclitaxel
Brand Names
Abraxane, Paclitaxel Protein-Bound
Paclitaxel
Brand Names
Abraxane, Paclitaxel Protein-Bound
Form: Injection
Method of administration: Intravenous
FDA approval date: March 01, 2004
Classification: Microtubule Inhibitor
ABRAXANE is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Dactinomycin
Generic Name
Dactinomycin
Dactinomycin
Generic Name
Dactinomycin
Form: Injection
Method of administration: Intravenous
FDA approval date: July 31, 2019
Classification: Actinomycin
Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen.
Trabectedin
Brand Names
EVDI, Yondelis
Trabectedin
Brand Names
EVDI, Yondelis
Form: Injection
Method of administration: Intravenous
FDA approval date: October 23, 2015
Classification: Alkylating Drug
EVDI is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen. EVDI is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )
Imatinib
Brand Names
Gleevec, Imkeldi
Imatinib
Brand Names
Gleevec, Imkeldi
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: May 15, 2001
Classification: Kinase Inhibitor
Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Showing 1-5 of 13
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances